SOURCE: Predictive Technology Group, Inc.

Predictive Technology Group, Inc.

November 17, 2015 10:55 ET

Predictive Technology Group, Inc. (PRED) Announces Issuance of US Patent for Endometriosis Treatment

VIRGINIA BEACH, VA--(Marketwired - Nov 17, 2015) -  Predictive Technology Group, Inc. (OTC PINK: PRED), a biotechnology company focused on personalized patient care through novel gene-based companion diagnostics and therapeutics, announces that the United States Patent and Trademark Office has issued US Patent 9,149,499 covering Progesterone/Progestin/Cannabis Therapeutic and Method of Use for the treatment of endometriosis. Predictive Therapeutics, LLC, a subsidiary of PRED, has exclusive rights to the patent.

About Endometriosis
According to the "The World Endometriosis Research Foundation," endometriosis affects an estimated 1 in 10 women during their reproductive years (i.e., usually between the ages of 15 to 49). Endometriosis is a condition where tissue, called endometrium, which lines the uterus is found outside the uterus inducing a chronic inflammatory reaction that may result in scar tissue. Endometriosis affects an estimated 176 million women worldwide regardless of their ethnic and social background. Many remain undiagnosed and are therefore not treated (http://endometriosisfoundation.org/Facts-about-endometriosis.pdf).

About Predictive Therapeutics
Predictive Technology Group, Inc. ("PRED") is a life sciences holding company. Predictive Therapeutics, LLC ("PRx"), a subsidiary of PRED, is focused on novel therapeutics leveraged by proprietary gene-based companion diagnostics that provide for the delivery of the most appropriate personalized patient care for the treatment of serious, chronic and debilitating diseases, www.predrx.com and www.predictivetechnologygroup.com.

For further information contact, Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Contact Information

  • Contact:
    Rich Kaiser
    YES INTERNATIONAL
    757-306-6090